Abiraterone acetate

• CAT Number: I001941
• CAS Number: 154229-18-2
• Molecular Formula: C26H33NO2
• Molecular Weight: 391.6
• Purity: ≥95%
• Target: P450
• Solubility: DMSO ≥18mg/mL Water <1.2mg/mL Ethanol ≥75mg/mL
• Storage: 3 years -20℃ powder
• IUPAC Name: [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
• InChI: InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21?,23?,24?,25-,26+/m0/s1
• InChIKey: UVIQSJCZCSLXRZ-UBUQANBQSA-N
• SMILES: C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5

Abiraterone acetate (Cat.No:I001941) is a medication used in the treatment of prostate cancer. It works by blocking the production of testosterone, which can stimulate the growth of cancer cells. Abiraterone acetate is taken orally and is typically used in combination with other medications. It has been approved for use in the United States and other countries around the world.

Reference

1:Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients/’ Satisfaction. Cindolo L, Natoli C, De Nunzio C, De Tursi M, Valeriani M, Giacinti S, Micali S, Rizzo M, Bianchi G, Martorana E, Scarcia M, Ludovico GM, Bove P, Laudisi A, Selvaggio O, Carrieri G, Bada M, Castellan P, Topazio L, Boccasile S, Ditonno P, Chiodini P, Schips L.Clin Genitourin Cancer. 2017 Apr 11. pii: S1558-7673(17)30087-3. doi: 10.1016/j.clgc.2017.04.003. [Epub ahead of print] PMID: 28478884 2:Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Kessler ER, Gao D, Flaig TW, Breaker K, Wold M, Wacker M, Lam ET.Ann Oncol. 2017 Mar 1;28(3):668. doi: 10.1093/annonc/mdw674. No abstract available. PMID: 28426121 3:Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies. Goldwater R, Hussaini A, Bosch B, Nemeth P.Clin Pharmacokinet. 2017 Apr 19. doi: 10.1007/s40262-017-0536-2. [Epub ahead of print] PMID: 28425029 4:Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. Rocha J, Aprikian AG, Vanhuyse M, Cury FL, Hu J, Prévost N, Dragomir A.CMAJ Open. 2017 Mar 28;5(1):E265-E272. doi: 10.9778/cmajo.20160082. eCollection 2017 Jan-Mar. PMID: 28401143 Free PMC Article5:Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer. Salem S, Komisarenko M, Timilshina N, Martin L, Grewal R, Alibhai S, Finelli A.Clin Oncol (R Coll Radiol). 2017 Apr 8. pii: S0936-6555(17)30141-3. doi: 10.1016/j.clon.2017.03.010. [Epub ahead of print] PMID: 28395931 6:Response to Letter to the Editor Regarding /Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal/. Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA.Pharmacoeconomics. 2017 Jun;35(6):665-667. doi: 10.1007/s40273-017-0507-3. No abstract available. PMID: 28391508 7:Comment on: /Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal/. Reifsnider O, Hall F, Sorensen S, Proskorovsky I, Girod I, Lee J.Pharmacoeconomics. 2017 Jun;35(6):661-663. doi: 10.1007/s40273-017-0502-8. No abstract available. PMID: 28390016 8:Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. Flaig TW, Plets M, Hussain MH, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IM Jr.JAMA Oncol. 2017 Mar 30. doi: 10.1001/jamaoncol.2017.0231. [Epub ahead of print] PMID: 28358937 9:The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R.Cancer Treat Rev. 2017 Apr;55:71-82. doi: 10.1016/j.ctrv.2017.03.001. Epub 2017 Mar 9. Review. PMID: 28340451 10:A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ.Oncologist. 2017 May;22(5):503-e43. doi: 10.1634/theoncologist.2016-0432. Epub 2017 Mar 17. PMID: 28314838 Free PMC Article